Physician profile
Arash Rashidi
NPI 1790774289
$113,178.95
in general payments reported to CMS, 2019-2025
9 companies · $84.75 in 2025
The $84.75 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $3,554 · 2021: $4,910 · 2022: $47K · 2023: $41K · 2024: $3,559 · 2025: $84.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Travel and Lodging: $4,535 · Consulting Fee: $2,000 · Food and Beverage: $836 · Education: $5.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,252.50 |
| Travel and Lodging | $4,535.29 |
| Consulting Fee | $2,000.00 |
| Food and Beverage | $835.91 |
| Education | $5.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $60,472.68 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $26,322.23 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $18,667.73 | 2022-2024 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $7,413.42 | 2022-2023 | |
| Glaxosmithkline, LLC. | $124.99 | 2023 | Benlysta |
| Btg International INC. | $84.75 | 2025 | Voraxaze |
| Renalytix Ai, INC. | $60.00 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Amgen INC. | $13.46 | 2024 | Tavneos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Rashidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.